These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25210852)

  • 1. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
    Wojton J; Meisen WH; Jacob NK; Thorne AH; Hardcastle J; Denton N; Chu Z; Dmitrieva N; Marsh R; Van Meir EG; Kwon CH; Chakravarti A; Qi X; Kaur B
    Oncotarget; 2014 Oct; 5(20):9703-9. PubMed ID: 25210852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.
    Blanco VM; Chu Z; Vallabhapurapu SD; Sulaiman MK; Kendler A; Rixe O; Warnick RE; Franco RS; Qi X
    Oncotarget; 2014 Aug; 5(16):7105-18. PubMed ID: 25051370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
    Wojton J; Chu Z; Mathsyaraja H; Meisen WH; Denton N; Kwon CH; Chow LM; Palascak M; Franco R; Bourdeau T; Thornton S; Ostrowski MC; Kaur B; Qi X
    Mol Ther; 2013 Aug; 21(8):1517-25. PubMed ID: 23732993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
    Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
    Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SapC-DOPS nanovesicles as targeted therapy for lung cancer.
    Zhao S; Chu Z; Blanco VM; Nie Y; Hou Y; Qi X
    Mol Cancer Ther; 2015 Feb; 14(2):491-8. PubMed ID: 25670331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas.
    Sulaiman MK; Chu Z; Blanco VM; Vallabhapurapu SD; Franco RS; Qi X
    Mol Cancer; 2015 Apr; 14():78. PubMed ID: 25889084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
    Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
    Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
    Pawlowska E; Szczepanska J; Szatkowska M; Blasiak J
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ.
    Sarkar S; Kumar S; Saha G; Basu M; Ghosh MK
    Int J Pharm; 2024 Nov; 665():124697. PubMed ID: 39270762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine.
    Winter PM; Pearce J; Chu Z; McPherson CM; Takigiku R; Lee JH; Qi X
    J Magn Reson Imaging; 2015 Apr; 41(4):1079-87. PubMed ID: 24797437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.